在癌症儿童中加强流感疫苗接种计划:一项前性开放性研究
Sung K Chiu1,2, Eliska Furlong1,3, Elizabeth J McKinnon1
1Leukaemia Translational Research Laboratory, WA Kids Cancer Centre, The Kids Research Institute Australia, Perth, WA, Australia.
NPJ vaccines
|August 25, 2025
概括
对接受癌症治疗的儿童提供额外剂量的加倍流感疫苗计划是安全有效的. 这种增强的免疫策略改善了抗体反应,为这种脆弱人群提供了更好的流感保护.
科学领域:
- 免疫学
- 儿童瘤学
- 疫苗学
背景情况:
- 标准的流感疫苗接种指导方针可能对免疫受损的儿童来说不足.
- 接受化疗的儿童对疫苗的免疫反应减弱.
研究的目的:
- 在儿童癌症患者中评估增强型流感疫苗接种方案的安全性和有效性.
- 评估对强化疫苗接种方案的体内免疫反应.
主要方法:
- 在接受癌症治疗的儿童中进行了前性开放性研究.
- 参与者接受了三个剂量 (年龄<9岁) 或两个剂量 (年龄≥9岁) 的流感疫苗,间隔至少4周.
主要成果:
- 增强的时间表被很好地容忍,没有严重的不良事件.
- 在流感A/ H1N1,A/ H3N2和B/ 华盛顿菌株中观察到几何平均抗体标位的显著改善.
- 增强的计划导致了对关键流感菌株的抗体水平的统计显著增加.
结论:
- 加强流感疫苗接种计划是接受癌症治疗的儿童的安全有效策略.
- 这种方法增强了体内免疫反应,提供了对流感的更好的保护.
- 这些发现支持实施这种强化疫苗接种计划,以保护免疫功能受损的儿童.
相关概念视频
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Vaccinations
45.3K
Overview
45.3K
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Rous Sarcoma Virus (RSV) and Cancer
5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.4K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


